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ABSTRACT 
Many actions of estradiol (E2), the principal physiological estrogen in vertebrates, are mediated by 
estrogen receptor-α (ERα) and ERβ.  An important physiological feature of vertebrate ERs is their 
promiscuous response to several physiological steroids, including estradiol (E2), Δ5-androstenediol, 
5α-androstanediol, and 27-hydroxycholesterol.  A novel structural characteristic of 
Δ5-androstenediol, 5α-androstanediol, and 27-hydroxycholesterol is the presence of a C19 methyl 
group, which precludes the presence of an aromatic A ring with a C3 phenolic group that is a 
defining property of E2.  The structural diversity of these estrogens can explain the response of the 
ER to synthetic chemicals such as bisphenol A and DDT, which disrupt estrogen physiology in 
vertebrates, and the estrogenic activity of a variety of plant-derived chemicals such as genistein, 
coumestrol, and resveratrol.  Diversity in the A ring of physiological estrogens also expands 
potential structures of industrial chemicals that can act as endocrine disruptors. Compared to E2, 
synthesis of 27-hydroxycholesterol and Δ5-androstenediol is simpler, leading us, based on 
parsimony, to propose that one or both of these steroids or a related metabolite was a physiological 
estrogen early in the evolution of the ER, with E2 assuming this role later as the canonical estrogen.  
In addition to the well-studied role of the ER in reproductive physiology, the ER also is an 
important transcription factor in non-reproductive tissues such as the cardiovascular system, kidney, 
bone, and brain.  Some of these ER actions in non-reproductive tissues appeared early in 
vertebrate evolution, long before mammals evolved. 
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1. Introduction 
1.1 Promiscuity in steroids that activate the estrogen receptor 
As our understanding of ligand-protein interactions has expanded, appreciation for the role 
of promiscuity as a force in evolution has increased [1-5].  The term ‘promiscuity’ is akin to that 
of ‘biological messiness’ [6].  We use promiscuity here as the capacity of the estrogen receptor 
(ER) to bind physiological steroids with diverse structures.  In particular, the A ring of estradiol 
(E2), the main physiological estrogen, differs from the A ring in Δ5-androstenediol, 
5α-androstanediol, and 27-hydroxycholesterol (Figure 1), as well as from the A ring of other classes 
of vertebrate adrenal and sex steroids (Figure 2).  Indeed, the aromatic A ring and C3 phenolic 
group, characteristic of E2, have been exploited to synthesize 'synthetic estrogens' that are used to 
treat estrogen-dependent diseases (Figure 3) [7, 8]. 
 
 
 
Figure 1. Promiscuity in ligands that are transcriptional activators of the estrogen receptor. 
The estrogen receptor is activated by steroids with diverse structures [8, 42, 44, 76].  Estradiol, the 
main physiological estrogen, contains an aromatic A ring with a C3-hydroxyl.  By contrast, 
Δ5-androstenediol, 5α-androstanediol, and 27-hydroxycholesterol contain a cyclohexane A ring, 
with a 3β-hydroxyl and a C19 methyl group. Δ5-Androstenediol and 27-hydroxycholesterol contain 
a B ring with an unsaturated bond between C5 and C6.  Δ5-Androstenediol, 5α-androstanediol, and 
27-hydroxycholesterol are physiological estrogens [27, 46, 50, 61, 67, 80].  Paraestrol A, a 
cholesterol analog with an aromatic A ring and a C3 phenolic group, has been proposed to be one of 
a class of cholesterol derivatives that may have been transcriptional activators of the ancestral 
estrogen receptor [15]. 
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Figure 2. Comparison of estradiol with other sex steroids and adrenal steroids. 
Testosterone, progesterone, cortisol, and aldosterone contain an A ring with an unsaturated bond 
between C4 and C5, a C3 ketone, and a C19 methyl group.  Estradiol has an aromatic A ring with 
a C3 hydroxyl and lacks a C19 methyl group.  The absence of a C19 methyl group in estradiol 
allows a close fit between the A ring on estradiol and ER and ERβ, as seen in the crystal structures 
of human ERα [34, 36] and ERβ [35, 113]. 
 
 
Figure 3. Synthetic estrogens. The role of an aromatic A ring with a C3-alcohol in the biological 
activity of estradiol provided a template for the synthesis of drugs to regulate estrogen action, such 
as diethylstilbestrol and 4-hydroxytamoxifen.  Diethylstilbestrol is a high-affinity agonist for both 
ER and ERβ [27], 4-hydroxytamoxifen is an important anti-estrogen, while tamoxifen, which 
lacks a phenolic A ring is inactive [27, 42]. 
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Unfortunately, various industrial chemicals containing phenolic groups can disrupt 
physiological responses to the ER in healthy people, and thus act as endocrine disruptors (Figure 4) 
[8-12].   
 
 
Figure 4. Synthetic chemicals that act as endocrine disruptors.  Many synthetic chemicals used 
in plastics and other industrial products contain a phenolic group that mimic the A ring of estradiol 
or two phenolic groups that mimic the A and D rings of estradiol [40, 77].  For example, bisphenol 
A, which is used in plastics and is widespread in the environment, is a xeno-estrogen [40, 41, 114].  
BPA can be metabolized to 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP), which has 
transcriptional activity at nM concentrations [115, 116].  Metabolism of the pesticide 
methoxychlor [1,1,1-trichloro-2,2-bis(4-methoxyphenyl)ethane] to HPTE 
(2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane) also yields an active xeno-estrogen that is 
approximately 100-fold more active than methoxychlor [75].  Interestingly, despite the absence of 
a phenolic group, o,p ́-DDT (2,2-bis(o,p-dichlorophenyl)-1,1,1-trichloroethane) is a pesticide with 
estrogenic activity [76, 77]. 
 
 
Interestingly, many natural products in plants also contain phenolic structures, which yield 
phytochemicals that are transcriptional activators of the ER (Figure 5) [8, 9, 13]. 
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Figure 5. Chemicals from plants that act as estrogens. 
Many chemicals in plants contain one or two 6-carbon rings with hydroxyl substituents that can 
mimic estradiol such that the phytochemical is an agonist for ER and ERβ [8, 40, 42, 43].  
Genistein [43] and coumestrol [77] contain aromatic structures that can mimic the A and D rings of 
estradiol.  Resveratrol is a phytoestrogen found in the skins of red grapes [13]. 
 
The diversity in the A ring of physiological estrogens (Figure 1) also expands the potential 
structures of chemicals that can be used as drugs for treating estrogen-dependent diseases in 
vertebrates, as well as of industrial chemicals that need to be screened for potential disruption of 
estrogen physiology [9, 14]. 
Synthesis of 27-hydroxycholesterol and Δ5-androstenediol is simpler than that of E2 [4, 9, 
15] (Figure 6), and this has important implications for the identity of the estrogen that was the 
transcriptional activator the ancestral ER [9, 16-18]. 
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Figure 6. Comparison of pathway for synthesis of estradiol, Δ5-androstenediol, and 
27-hydroxycholesterol.   E2 is synthesized in three enzymatic steps from 
dehydroepiandrosterone (DHEA) [4, 80].  By contrast, Δ5-androstenediol is synthesized from 
DHEA in one step [46, 53].  27-Hydroxycholesterol is synthesized in one step from cholesterol. 
 
The earliest ortholog of mammalian ER is found in amphioxus [4, 15, 19-21], a marine 
chordate that diverged from vertebrates more than 520 million years ago.  Based on parsimony, we 
propose that one or both of these C19-containing steroids or a related metabolite were ligands for 
the early chordate ER, with E2 evolving later as the canonical estrogen [9, 16].  Many actions of 
the ER in non-reproductive tissues evolved in vertebrates long before the evolution of mammals, in 
which reproductive activity of the ER has long been a main focus [22, 23].  An evolutionary 
perspective of ER signaling [9, 24] provides insights into its promiscuous actions in different 
tissues: brain, heart, bone, and kidney, as well as traditional ER activities in reproductive organs. 
 
2. Estradiol, a hormone with many physiological actions in females and males 
Owing to its key role in female reproduction, E2 often is described as a 'female' sex 
hormone. However, E2 also is an important steroid in males [25, 26].  The physiological actions of 
E2 and other estrogens are mediated by two ER isoforms, ERα and ERβ [27-29].  Through 
transcriptional activation of these ERs, estrogens regulate variety physiological responses in 
reproductive organs [22, 23, 26, 28], brain [30-33], bone, and the cardiovascular system [22]. 
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3. What is an estrogen? 
E2 is the major physiological ligand for the vertebrate ERs [23, 28].  Compared to other 
adrenal and sex steroids, E2 is a compact hydrophobic molecule with few side chains that could 
interact with the ER (Figure 2).  The aromatic A ring on E2 is unique among adrenal and sex 
steroids (Figure 2).  The crystal structures of ERα and ERβ provide insights into the key contacts 
between E2 and the ER [8, 34, 35].  Owing to the aromatic chemistry in the A ring, the C3-alcohol 
can function as a hydrogen-bond donor and acceptor with Arg-394 and Glu-353 in human ERα [8, 
34] (Figure 7) and with Arg-346 and Glu-305 in ERβ [35].  In addition, because of the aromatic A 
ring, the interface between the A and B ring is flat and E2 lacks a C19 methyl group, which allows 
ERα and ERβ to form a close contact with this part of E2 (Figure 7) [8, 14, 34, 35].  By contrast, 
testosterone and other 3-ketosteroids (Figure 2) have a different A ring and contain a C19 methyl 
group, and thus their receptors use a different chemistry to contact the A ring [36-38]. 
 
 
Figure 7. Structure of ER with 17β-estradiol [34, 117]. 
ERα (PDB: 1G50) [117] was used for this figure.  The C3-hydroxyl on E2 forms hydrogen bonds 
with Glu-353 and Arg-394 on ERα.  The 17β-hydroxyl has a hydrogen bond with His-524. 
 
Also important in binding of E2 to the ER is the hydroxyl on the D ring, which has a 
stabilizing contact with His-524 in ERα (Figure 7) and with His-475 in ERβ [8, 9, 34, 35]. 
The spatial relationship of the functional groups on the A and D rings on E2 has been used 
to develop chemicals containing properly spaced A and D rings that are either estrogens, such as 
diethylstilbestrol (DES) or anti-estrogens such as 4-OH-tamoxifen (4-OH-TAM) and raloxifene [7, 
8, 34, 36, 39] (Figure 3). 
Many synthetic chemicals in the environment contain a phenolic group corresponding to the 
A ring on E2 and often contain a D ring with some similarity to the D ring on E2, which together 
promotes binding to the ER, disrupting normal estrogen physiology (Figure 4) [10, 11, 40].  For 
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example, the phenolic hydroxyls on bisphenol A (BPA) contact Arg-394 and Glu-353 and His-524 
in human ERα (Figure 8) [14, 41]. 
 
 
Figure 8. Structure of ER with bisphenol A. 
ERα (PDB: 3UU7) [41] was used for this figure.  The A ring on BPA forms hydrogen bonds with 
Glu-353 and Arg-394 in ERα.  The hydroxyl on the second ring forms a hydrogen bond with 
His-524. 
Similarly, many chemicals in plants contain an aromatic A ring corresponding to the A ring 
and a second 6-carbon ring that can mimic the D ring on E2 (Figure 5), which promotes binding 
with nM Kd and transcriptional activation of ERα and ERβ [11, 40, 42].  For example, genistein 
(Figure 9) [43] and E2 (Figure 7) have similar contacts between their A rings and Arg-394 and 
Glu-353 in human ERα, and Arg-346 and Glu-305 in ERβ, as well as their D rings and His-524 in 
ERα, and His-475 in ERβ [14, 43]. 
 
Figure 9. Structure of ER with genistein.  ERα (PDB: 1X7R) [43] was used for this figure.  
The A ring on genistein forms hydrogen bonds with Glu-353 and Arg-394 in ER.  The hydroxyl 
group on the D ring on genistein forms a hydrogen bond with His-524. 
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4. Activities of estrogens with novel structures 
In the past decade the concept that a steroid must have an aromatic A ring with a 
C3-phenolic group to be a physiological estrogen has undergone revision because steroids with a 
different A ring have been shown to be transcriptional activators of ERα and ERβ, and thus act as 
physiological estrogens [30, 44-47].  Δ5-Androstenediol, 5α-androstanediol, and 
27-hydroxycholesterol (Figure 1) are examples of physiological estrogens that do not contain an 
aromatic A ring with a C3 phenolic group, and thus expand the potential structures of physiological 
ligands for the ER.  Phytochemicals and synthetic industrial chemicals also have structures that 
differ from that of E2.  Below we briefly review some physiological activities of these estrogens 
with novel structures. 
 
4.1 Δ5-Androstenediol 
Δ5-Androstenediol (Figure 1) competes with E2 for binding to the ER in rat uterus cytosol 
[48, 49] and has estrogenic activity in MCF-7 cells [50].  Competitive analysis of binding of 
Δ5-androstenediol to purified human ER and rat ERβ found that Δ5-androstenediol had a Ki of 3.6 
nM and 0.9 nM, respectively, for human ER and rat ERβ [27]. 
Δ5-Androstenediol binding to ERβ in astrocytes and microglia inhibits activation of 
inflammatory response genes [46, 51].  Δ5-Androstenediol is synthesized in brain microglia [52, 
53]. Inhibition of inflammation in microglia is important in a variety of neurodegenerative diseases 
[54, 55], including multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis [56-58]. 
Interestingly, E2 is not a potent repressor of inflammation in microglia, and 5-androstanediol has 
weak activity [46, 51]; that is, Δ5-androstenediol has a physiological activity that is absent in E2.  
Thus, displacement by E2 of Δ5-androstenediol from ERβ counteracts the inhibitory effect of 
Δ5-androstenediol on inflammation.  This counteracting effect of E2 on Δ5-androstenediol 
inhibition of inflammation in the brain microglia may explain higher incidence of multiple sclerosis 
in women [51, 59, 60].  Interestingly, binding by the phytoestrogen coumestrol to ERβ (Figure 5) 
also inhibits inflammation in microglia. However, the phytoestrogen genistein has no effect [46]. 
 
4.2 5α-Androstanediol 
Analysis of binding of 5α-androstanediol to purified human ER and rat ERβ found that 
5α-androstanediol had Ki values of 6 nM and 2 nM, respectively, for human ER and rat ERβ [27].  
5α-Androstanediol binding to ERβ has a role in controlling prostate growth [30, 61, 62] and 
inflammation in the brain [31, 63].  Indeed, 5α-androstanediol may be a second physiological 
estrogen in the brain [30, 31, 63]. 
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Owing to the decline in E2 synthesis after menopause, circulating Δ5-androstenediol [64-66] 
may be important physiological estrogens in post-menopausal women. 
 
4.3. 27-Hydroxycholesterol 
27-Hydroxycholesterol appears to be a transcriptional regulator of both ERα and ERβ [47, 
67-69].  27-Hydroxycholesterol binding to ERα reduces bone density [69, 70].  The Kd values of 
27-hydroxycholesterol for ERα and ERβ are about 1.3 μM and 0.4 μM, respectively [47, 67, 68], 
which are over 10
3
-fold higher than the Kd of E2 for human ERα and ERβ [27].  Levels of 
circulating 27-hydroxycholesterol are in the range 0.15 to 0.73 μM [47, 67, 71]. 
27-Hydroxycholesterol acts through activation of ER to promote the growth of 
ER-dependent breast tumors [72].  At 10 nM, 27-hydroxycholesterol promoted MCF-7 cell and 
Ishikawa cell proliferation [73]. 
 
4.4. Paraestrol A 
Paraestrol A is a recently described steroid that resembles cholesterol and with an aromatic 
A ring (Figure 1).  Paraestrol A has been proposed to be an ancestral estrogen [15]. Although this 
steroid has not been found in mammals, clearly paraestrol A or a metabolite, such as 
27-OH-paraestrol A, must be considered as a possible 'first' transcription activator of the ER in 
amphioxus or another chordate in which the first steroid-activated ER evolved [9, 15, 19, 74]. 
 
4.5. Phytochemicals 
Many plants synthesize chemicals that have sufficient structural similarity to E2 so as to 
bind ER and ERβ [8, 13, 14, 42] (Figure 5).  These chemicals have an A ring with an alcohol at 
C3 and a 6-carbon D ring.  Despite the different D ring structures in genistein (6-carbon ring) and 
E2 (5-carbon ring), the alcohol on the genistein D ring conserves a key contact with Nδ1 on His524 
in ER (Figure 9).  The role of these phytoestrogens in plants is not fully understood, although 
protection against herbivores through phytoestrogen interference in herbivore physiology is one 
possibility.  There is increased interest in the use of these phytoestrogens in human health [13]; 
however, their benefits remain controversial. 
 
4.6 Environmental chemicals and endocrine disruptors 
A major concern regarding the health of the environment is that many synthetic chemicals 
have structures that allow binding to ER and ERβ [8, 9, 14, 42] (Figure 4).  For example, 
bisphenol A (BPA) and E2 conserve key binding interactions with ER (Figure 8). Metabolism of 
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pesticide methoxychlor to HPTE results in an xenoestrogen with approximately 100-fold more 
activity demonstrating the importance of the phenolic group [75].  Unexpectedly, DDT 
(dichlorodiphenyltrichloroethane), which lacks alcohol substituents, is nevertheless a xenoestrogen 
[76, 77] 
 
5. An evolutionary perspective. What is the ancestral estrogen and what were its ancestral 
physiological activities; that is, why is E2 more than a reproductive hormone? 
The traditional model is that E2 and its metabolites are the main physiological estrogens in 
mammals, and thus the estrogenic actions of Δ5-androstenediol, 5α-androstanediol, and 
27-hydroxycholesterol which lack an aromatic A ring are perplexing.  The physiological actions of 
ERα and ERβ in non-reproductive tissues, such as the brain, also deserve elucidation.  To begin to 
provide a perspective on these phenomena, we draw on Dobzhansky [78] with a modified paradigm 
'Nothing in estrogen physiology makes sense except in the light of evolution'.  We use this 
evolutionary perspective [9, 79, 80] to investigate various inter-related questions including when 
did the ER arise, what were the ligand(s) that activate the ancestral ER receptor, and what were the 
physiological actions of the ER in basal chordates and vertebrates? 
 
5.1 When did the ER arise? 
Nuclear receptors are found in basal animals, but not in plants, yeast, or bacteria [81-86].  
Receptors for adrenal and sex steroids evolved in deuterostomes [18, 81, 82, 85-88].  Sequence 
analysis indicates that the ER evolved before the AR, GR, MR, and PR [4, 18, 74, 87].  
Amphioxus, a protochordate in the line leading to vertebrates, contains an ancestral ER and another 
steroid receptor (SR), which appears to be the ancestor of the 3-ketosteroid receptors [19-21, 89]. 
Interestingly, E2 does not bind to amphioxus ER.  However, E2 is a transcriptional activator of the 
SR, which is not activated by androgens, glucocorticoids, mineralocorticoids, or progestins [19-21]. 
 
5.2 What was the ancestral estrogen? 
Thus far, only E2 and E1 have been found to be transcriptional activators of amphioxus SR 
[19, 20].  Other potential estrogens such as Δ5-androstenediol, 5α-androstanediol, 
27-hydroxycholesterol, and paraestrol A have not been tested for activation of amphioxus SR.  
The synthesis of these steroids is more parsimonious than the pathway for the synthesis of E2 
(Figure 6).  In fact, synthesis of testosterone is simpler than that of E2.  Indeed, testosterone is an 
intermediate in the synthesis of E2, suggesting that the AR should have evolved before the ER. 
Two hypotheses have been advanced to explain the puzzle that E2 is an ancestral ligand for 
the SR despite the more complex synthesis of E2 relative to testosterone.  Both hypotheses rely on 
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the identity of the ancestral estrogen.  In one hypothesis, based on E2 being the ancestral estrogen, 
Thornton [17-19] proposed the novel 'ligand exploitation' model in which E2 was the ancestral 
ligand for the first ER, and testosterone was inactive because the AR had not yet evolved [19].  
Through gene duplication and sequence divergence of an ancestral SR, receptors for the AR and 
other 3-ketosteroid receptors evolved.  In this model, the evolution of the AR 'exploited' the 
presence of testosterone as a biological intermediate in estrogen synthesis [17-19].  Further gene 
duplications led to the evolution of the other adrenal and sex steroid receptors. 
A more conventional model uses parsimony in the pathway for synthesis of estrogens is to 
identify the ancestral estrogen(s) [9, 16].  The ancestral estrogen is proposed to be 
Δ5-androstenediol, which is synthesized in one step from dehydroepiandrosterone (DHEA) (Figure 
6) [9, 16].  Synthesis of Δ5-androstenediol does not require either aromatase or 
3β,Δ4–5-hydroxysteroid dehydrogenase, providing a more parsimonious synthesis than for either E2 
or E1, which requires both enzymes. 
The evidence that Δ5-androstenediol is a high-affinity ligand for the ER supports 
considering this steroid as a ligand for the ancestral ER.  5α-Androstanediol, 
27-hydroxycholesterol, and paraestrol A also may be ligands for the ancestral ER.  Of the three 
steroids with a C19 methyl group, the synthesis of 27-hydroxycholesterol from cholesterol is the 
most parsimonious [9] (Figure 6).  The recent report by Markov et al. [15] of paraestrol A, an 
aromatized cholesterol derivative, provides another potential ancestral ligand for the ER. 
 
6. ER and ERβ are expression in the brain: transcriptional activation by 5α-androstanediol 
and Δ5-androstenediol 
The presence of an ER and SR in ovaries and testis in amphioxus indicates that some 
reproductive functions of estrogens in males and females evolved in a basal chordate [19, 20, 90], 
although transcriptional activation of the ER in uterus or prostate evolved hundreds of millions of 
years after the evolution of amphioxus, lamprey, and coelacanth.  As mentioned above, the ER has 
physiological actions in the brain.  ER and ERβ are reported to be expressed in different regions 
in the brain during development in males and females [28, 30, 91-94].  Thus, E2 is a neurosteroid, 
as well as a reproductive steroid.  Moreover, Δ5-androstenediol and 5α-androstanediol, which have 
a different A ring than E2, have been found to be transcriptional activators of the brain ER [30, 46]. 
The estrogenic activity of steroids with a C19 methyl group may provide a selective 
advantage in estrogen physiology that is not provided by E2.  In this regard, 5α-androstanediol has 
been proposed to be a second physiological estrogen in fetal mouse brain based on the timing of 
ERβ synthesis in mouse brain, which begins at embryonic day 10.5 [30, 95, 96], well before 
embryonic day 18.5 when aromatase (which catalyzes the synthesis of E2) is first expressed.  Thus, 
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there are at least two physiological estrogens in mouse brain.  Moreover, other studies find that 
ERβ mediates the actions of 5α-androstanediol in human brain cells [31, 63]. 
In addition, Δ5-androstenediol is synthesized in the brain [52, 53], providing a third 
endogenous estrogen in mouse brain.  Finally, 27-hydroxycholesterol also is present in the brain 
[97].  Thus, there may be four physiological neuro-estrogens.  The unique anti-inflammatory 
response in brain microglia due to binding of Δ5-androstenediol to ERβ may be the first of a series 
of specialized physiological activities for Δ5-androstenediol, 5α-androstanediol, and 
27-hydroxycholesterol in the brain and other organs.  It is interesting that E2 and 
Δ5-androstenediol regulate different physiological responses through ERβ in microglia. 
We propose that some activities of the ER in different regions of the mammalian brain [30, 
32, 33, 98] were important in amphioxus or in lamprey.  Although the head and brain are poorly 
developed in amphioxus [99-102], many genes in amphioxus are expressed in the brain in lamprey 
and other vertebrates [100, 102, 103].  It appears that these genes were important in the evolution 
of the brain during the transition from amphioxus to lamprey [100-102].  It is tempting to 
speculate that transcriptional regulation of the SR in an ancestral amphioxus by Δ5-androstenediol, 
5α-androstanediol, 27-hydroxycholesterol, or paraestrol A, as well as by E2, was important in brain 
evolution [79, 80], which would place the origins of responses to estrogens in the brain as 
contemporary with its reproductive actions. 
Also relevant for the evolution of estrogen physiology is the presence in lamprey of a PR 
and corticoid receptor (CR) [4, 18, 104], which is the ancestor of the GR and MR [4, 104].  These 
steroid receptors have transcriptional properties that similar to their mammalian orthologs [38, 105].  
Crosstalk between the ER and the PR, GR, and MR may have contributed to the evolution of the 
brain [106-108] and other organs during the transition from amphioxus to lamprey. 
 
7. Future research 
There is a need to verify the presence of Δ5-androstenediol, 5α-androstanediol, and 
27-hydroxycholesterol in amphioxus and lamprey to provide evidence for the physiological activity 
of these 3-ketoestrogens early in the evolution of the ER.  Synthesis of Δ5-androstenediol, 
5α-androstanediol, and 27-hydroxycholesterol in amphioxus and lamprey can be studied through 
metabolism of radioactive cholesterol in tissue extracts from amphioxus and lamprey.  Of course, 
transcriptional activation of amphioxus SR and lamprey ER by Δ5-androstenediol, 
5α-androstanediol, and 27-hydroxycholesterol will be necessary to determine their biological 
activity in relation to E2.  The functions of 3-keto-estrogens in mammals merit further study in 
view of the evidence that 5α-androstanediol and Δ5-androstenediol are important in prostate [61] 
and brain microglia [46, 51], respectively.  Investigation of Δ5-androstenediol, 5α-androstanediol, 
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and 27-hydroxycholesterol actions in tissues with ERα and ERβ during different stages in 
development may uncover additional physiological responses mediated by these 'alternative' 
estrogens.  In this regard, the slow continuous increase in DHEA synthesis from birth, which is 
coupled with increased synthesis of Δ5-androstenediol [109], merits further study, as does the role 
of Δ5-androstenediol during fetal development [110], when DHEA levels are high [111, 112]. 
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